Hematologic Malignancies

BeiGene is advancing a hematologic malignancy pipeline consisting of novel oral small molecules and monoclonal antibodies. Among these are zanubrutinib, a next-generation Bruton's tyrosine kinase inhibitor and BGB-11417, a BCL2 inhibitor, both for the treatment of various B-cell malignancies.
All Types
All Types
Reading
4
Slide-Kit
6
Video
5
Latest
Latest
latest
Oldest
oldest
All Types
All Types
Reading
4
Slide-Kit
6
Video
5
Latest
Latest
latest
Oldest
oldest
Suggested:
CLL
EHA
ESMO
Hematologic Malignancies
Solid Tumors
WM

Zanubrutinib MoA

Zanubrutinib is a next-generation Bruton’s tyrosine kinase inhibitor (BTKi) designed for selectivity, potency, and bioavailability. Watch the mode of action (MoA) video to learn more.

Video
29 May 2024

Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind and inhibit PD‑1. Watch the mode of action (MoA) video to learn more.

Video
29 May 2024